Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Leukemia
•
ALL
•
AYA
•
Hematology
•
Pediatric Oncology
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
In treatment naive patients with del 17p/TP53 negative CLL, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial (published in the NEJM) change your practice?
For patients with Stage IIIB or IV HD flowing Bv-AVEPC with initial large mediastinal adenopathy, how can we avoid ISRT?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
